6kn9: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of human interleukin 18 receptor beta extracellular domain in complex with an antagonistic scFv== | |||
<StructureSection load='6kn9' size='340' side='right'caption='[[6kn9]], [[Resolution|resolution]] 3.30Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6kn9]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6KN9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6KN9 FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6kn9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6kn9 OCA], [http://pdbe.org/6kn9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6kn9 RCSB], [http://www.ebi.ac.uk/pdbsum/6kn9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6kn9 ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The interleukin-18 subfamily belongs to the interleukin-1 family and plays an important role in modulating innate and adaptive immune responses. Dysregulation of IL-18 has been implicated in or correlated with numerous diseases, including inflammatory diseases, autoimmune disorders, and cancer. Thus, blockade of IL-18 signaling may offer therapeutic benefits in many pathological settings. Here, we report the development of synthetic human antibodies that target human IL-18Rbeta and block IL-18-mediated IFN-gamma secretion by inhibiting NF-kappaB and MAPK dependent pathways. The crystal structure of a potent antagonist antibody in complex with IL-18Rbeta revealed inhibition through an unexpected allosteric mechanism. Our findings offer a novel means for therapeutic intervention in the IL-18 pathway and may provide a new strategy for targeting cytokine receptors. | |||
A Synthetic Human Antibody Antagonizes IL-18Rbeta Signaling Through an Allosteric Mechanism.,Liu S, Miersch S, Li P, Bai B, Liu C, Qin W, Su J, Huang H, Pan J, Sidhu SS, Wu D J Mol Biol. 2020 Jan 15. pii: S0022-2836(20)30042-5. doi:, 10.1016/j.jmb.2020.01.012. PMID:31954129<ref>PMID:31954129</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6kn9" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Liu, C C]] | |||
[[Category: Wu, D H]] | |||
[[Category: Antagonist]] | |||
[[Category: Antibody]] | |||
[[Category: Complex]] | |||
[[Category: Cytokine]] | |||
[[Category: Interleukin receptor]] | |||
Revision as of 04:13, 13 February 2020
Crystal structure of human interleukin 18 receptor beta extracellular domain in complex with an antagonistic scFv
| ||||||||||||
